DBV Technologies to Announce Q3 2026 Financial Results

DBV Technologies, a late-stage biopharmaceutical company, will present its third quarter 2026 financial results on October 28. The announcement will take place during an investor conference call at 5:00 p.m. ET. Investors are invited to join the call to receive insights into the company's financial performance and business strategies.

DBV specializes in developing treatments for food allergies and immunologic conditions using its proprietary VIASKIN® patch technology. This patch aims to offer a non-invasive treatment option for food allergies by desensitizing the immune system against allergens.

The company's shares are listed on Euronext Paris and the Nasdaq Capital Market, reflecting their international presence. The upcoming results will likely provide stakeholders an understanding of the company's progress in its ongoing clinical trials, especially focusing on young children with peanut allergies.